BIOLEX COMPLETES STUDY OF BLX-883
Biolex Therapeutics has announced the successful completion of a Phase I clinical
trial of BLX-883, a form of alfa interferon. BLX-883 is the company's clinical-stage
therapeutic candidate.
In the study, BLX-883 was safely administered at a clinically relevant dose
and demonstrated bioactivity consistent with Intron A, a currently marketed
alfa interferon used as a comparator. Alfa interferon is used in the treatment
of hepatitis C, hepatitis B, and multiple cancers.
The study was designed to evaluate the safety and pharmacology of BLX-883 in
24 healthy volunteers. Participants were administered one of three doses of
BLX-883. The 12 participants who received the clinically relevant dose of 3
million international units also received the same dose of Intron A to allow
for a direct comparison of the two agents. No safety concerns arose during the
study, and the side-effects attributable to BLX-883 and Intron A were comparable.
Bioactivity of the two agents was also compared, and the elevation of specific
immune system markers, such as neopterin, measured after administration of BLX-883
was consistent to the elevation measured after administration of Intron A.
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May